Skip to content

Urine DNA Markers for Repeat TURBT: A Multicenter RCT

A multicenter randomized controlled trial evaluating urine DNA biomarkers for precision selection of patients requiring repeat transurethral resection in non-muscle-invasive bladder cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128255
Enrollment
Unknown
Registered
2026-07-16
Start date
2026-07-19
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Interventions

Control Group:Repeat TURBT was performed within 8–12 weeks after the initial resection. Patients with negative pathological findings will undergo follow?up examinations every 3 months, including cysto
Intervention group:Patients with a positive utDNA MRD test result underwent repeat TURBT, whereas those with a negative result did not receive repeat resection.

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years or older with clinically confirmed intermediate- to high-risk non-muscle-invasive bladder cancer (NMIBC). 2. Histologically confirmed as urothelial carcinoma. 3. Patients with NMIBC who met the guideline-recommended indications for repeat TURBT; 4. A 100 mL morning urine sample (first void) is required at each designated time point.

Exclusion criteria

Exclusion criteria: 1.Patients with confirmed residual tumor at the initial TURBT. 2.Patients who had been enrolled in any drug clinical trial within 3 months before study entry. 3.Any condition that, in the judgment of the investigator, could potentially increase the risk to the participant or compromise the execution of the clinical trial.

Design outcomes

Primary

MeasureTime frame
The difference in the pathological positive rate of Re-TURBT between the study group and the control group (i.e., an increase in the positive rate of repeat resection;The difference in the disease-free rate at 3 months post-intervention between the study group (utDNA MRD testing) and the control group (routine surveillance) was assessed as the primary endpoint ;

Secondary

MeasureTime frame
The disease recurrence rates at 6 and 12 months after intervention ;The sensitivity and specificity of urinary utDNA MRD testing.;The difference in total costs for the diagnosis and treatment of NMIBC.;

Countries

China

Contacts

Public ContactPengjie Wu

Beijing Hospital

wupengjie4598@bjhmoh.cn+86 10 85136272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026